1. Home
  2. VNO vs HALO Comparison

VNO vs HALO Comparison

Compare VNO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vornado Realty Trust

VNO

Vornado Realty Trust

HOLD

Current Price

$39.08

Market Cap

6.3B

Sector

Real Estate

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

N/A

Current Price

$98.41

Market Cap

11.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VNO
HALO
Founded
1946
1998
Country
United States
United States
Employees
N/A
423
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
11.6B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
VNO
HALO
Price
$39.08
$98.41
Analyst Decision
Hold
Buy
Analyst Count
10
11
Target Price
$33.00
$78.64
AVG Volume (30 Days)
1.7M
2.2M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
2.52%
N/A
EPS Growth
10400.00
N/A
EPS
N/A
3.11
Revenue
$1,810,425,000.00
$151,862,000.00
Revenue This Year
N/A
$28.24
Revenue Next Year
$5.42
$12.56
P/E Ratio
N/A
$32.36
Revenue Growth
1.27
N/A
52 Week Low
$24.57
$61.23
52 Week High
$43.37
$104.78

Technical Indicators

Market Signals
Indicator
VNO
HALO
Relative Strength Index (RSI) 48.74 73.74
Support Level $37.94 $67.12
Resistance Level $39.27 N/A
Average True Range (ATR) 1.15 3.12
MACD -0.18 1.42
Stochastic Oscillator 18.65 73.42

Price Performance

Historical Comparison
VNO
HALO

About VNO Vornado Realty Trust

Vornado Realty Trust is a fully integrated real estate investment trust with a portfolio of New York City office, retail, and multifamily assets, and the developer of the new Penn District. While concentrated in New York, the trust also owns assets in both Chicago and San Francisco. It generates revenue in the form of property rentals, fees charged for trade shows, parking revenues, management and leasing fees, etc. Vornado operates in the following reportable segments: New York (its key revenue-generating market) and Other.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: